How I manage patients with relapsed/refractory diffuse large B cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Diffuse large B cell lymphoma (DLBCL) frequently relapses despite upfront treatment.
• Salvage chemotherapy with autologous stem cell transplantation (ASCT) is the standard second-line therapy for relapsed/refractory (R/R) DLBCL.
• Many patients are ineligible for ASCT or relapse post-transplant, highlighting unmet needs in R/R DLBCL management.

Purpose of the Study:

• To review current treatment strategies for R/R DLBCL.
• To identify challenges and unmet needs in managing patients with refractory DLBCL.
• To discuss emerging therapies, including CAR T-cell therapy, for R/R DLBCL.

Main Methods:

• Review of existing literature and clinical trial data.
• Analysis of outcomes from studies like SCHOLAR-1 and frameworks like CORAL.
• Discussion of treatment efficacy, prognostic factors, and novel therapeutic approaches.

Main Results:

• No single salvage chemotherapy regimen shows superiority in randomized trials.
• The SCHOLAR-1 study reported a 26% objective response rate and 6.3-month median overall survival for subsequent therapies in refractory DLBCL.
• Long-term survival is achievable with ASCT following response, but salvage efficacy needs improvement.

Conclusions:

• There is a critical need for novel therapeutic agents to enhance salvage treatment efficacy in R/R DLBCL.
• Chimeric antigen receptor T-cell (CAR-T) engineering shows promise and warrants further investigation in controlled studies.
• Optimizing treatment strategies for R/R DLBCL, particularly for third-line therapy, remains a significant clinical challenge.